{
    "organizations": [],
    "uuid": "f3e1189d1068bd7487722d6c69d05bf87fc0a8df",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-catalyst-biosciences-provides-corp/brief-catalyst-biosciences-provides-corporate-update-idUSASB0C8C4",
    "ord_in_thread": 0,
    "title": "Catalyst Biosciences Provides Corporate Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Catalyst Biosciences Inc:\n* CATALYST BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* CATALYST BIOSCIENCES - ‍CASH BALANCE OF OVER $135 MILLION AFTER FEB FOLLOW-ON FINANCING ALLOWS FOR INDEPENDENT DEVELOPMENT OF LEAD PROGRAMS​\n* CATALYST BIOSCIENCES INC - ‍COMPANY HAS NO OUTSTANDING NOTES OR DEBT​\n* CATALYST BIOSCIENCES INC - ‍INTEREST AND OTHER INCOME FOR QUARTER WAS $0.1 MILLION, VERSUS $1.5 MILLION FOR PRIOR YEAR PERIOD​ Source text for Eikon:\n ",
    "published": "2018-03-01T22:13:00.000+02:00",
    "crawled": "2018-03-02T20:15:08.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "catalyst",
        "bioscience",
        "inc",
        "catalyst",
        "bioscience",
        "report",
        "fourth",
        "quarter",
        "operating",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "catalyst",
        "bioscience",
        "balance",
        "million",
        "feb",
        "financing",
        "allows",
        "independent",
        "development",
        "lead",
        "catalyst",
        "bioscience",
        "inc",
        "outstanding",
        "note",
        "catalyst",
        "bioscience",
        "inc",
        "income",
        "quarter",
        "million",
        "versus",
        "million",
        "prior",
        "year",
        "source",
        "text",
        "eikon"
    ]
}